This is a routine Form 3 filing with no trading signal. Monitor for future Form 4 filings from Ms. Vousden for any open-market purchases or sales that could provide insider sentiment. The 42,631 share position is small relative to the company's $1.0B market cap and does not indicate material alignment or concern.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 16 $34.24entry
- T+1 · 2mo ago +2.60%α +1.47% · $35.13
- T+5 · 8w ago −7.86%α −10.42% · $31.55
- T+20 · 5w ago −37.18%α −40.36% · $21.51
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
How similar events traded
Executive Summary
Karen H. Vousden filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting 42,631 shares of Faeth Therapeutics common stock held directly. This is a routine filing required upon becoming a reporting person (officer, director, or >10% holder) and does not reflect a new purchase or sale, nor does it provide any material financial or operational information about the company.
Key Facts
- Karen H. Vousden filed a Form 3 initial statement of beneficial ownership on September 15, 2026, for the period ending September 11, 2026.
- The filing reports 42,631 shares of Faeth Therapeutics common stock held directly by Ms. Vousden.
- A Power of Attorney (Exhibit 24) was included, authorizing Christopher Gerry and Josiah Craver to execute future Forms 3, 4, and 5 on her behalf.
- This filing is a routine administrative requirement for new reporting persons under Section 16(a) of the Exchange Act.
Financial Impact
No financial impact, the filing reports an existing beneficial ownership position, not a transaction.
Risk Factors
- No material risks identified from this filing; it is purely administrative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001723884-26-000004 |
| Document: 0001723884-26-000004-index-headers.html | 0001723884-26-000004 |
| Document: 0001723884-26-000004-index.html | 0001723884-26-000004 |
| Document: 0001723884-26-000004.txt | 0001723884-26-000004 |
Track record
12 reports on FTH
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +35.00% at T+60 after the Aug 11, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $10.03 −0.00% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $10.03 −20.90% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $10.03 −20.90% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $10.03 −48.96% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $10.03 −47.76% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $10.03 −47.51% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Viewing Entry $34.24 to $35.13 Now $10.03 −70.71% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $10.03 +66.57% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Entry $25.50 to $24.59 Now $10.03 −60.67% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers